Humanized anti-interleukin-6 receptor antibody

By L. Moreland. 2005

648 citations recorded by the source corpus.

Subfields: Radiology, Nuclear Medicine and Imaging, Rheumatology

View Paper: https://www.semanticscholar.org/paper/88df004da6c200d93e0aad7bb4224cdf75f73539

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Radiology, Nuclear Medicine and Imaging

1. S. Rose‐John
2. Simon A. Jones
3. J. Scheller
4. Toshio Tanaka
5. T. Kishimoto
6. N. Nishimoto
7. M. Narazaki
8. I. Tannock

In Rheumatology

1. T. Kishimoto
2. N. Nishimoto
3. S. Rose‐John
4. Simon A. Jones
5. J. Scheller
6. Toshio Tanaka
7. M. Narazaki

Citations in the corpus

• IL-6 in inflammation, immunity, and disease. (2014, background): “…et al. 1988), swollen lymph nodes of Castleman’s disease (Yoshizaki et al. 1989), myeloma cells (Kawano et al. 1988), and peripheral blood cells or involved tissues in various other autoimmune and chronic inflammatory diseases and even malignant cells in cancers (Nishimoto et al. 1989, 2005).”
• Cytokines and their relationship to the symptoms and outcome of cancer (2008, background): “In a prospective study of patients with Castleman disease, which is a lymphoproliferative disorder characterized by increased production of IL6, administration of a monoclonal antibody against IL6R was strongly associated with reduced fatigu”
• Interleukin‐6 biology is coordinated by membrane‐bound and soluble receptors: role in inflammation and cancer (2006, background): “Therefore, one can predict that the treatment of asthma patients with the sgp130Fc protein would reduce Th2 cells in the lung and that blockade of the membrane-bound IL-6R by the neutralizing antibody MRA [119] would increase the number of Treg cells in the lung, thereby reducing the local number of”
• IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6 (2012, background): “Indeed, it was already noted in a clinical trial with IL-6R neutralizing antibodies that patients with multicentric Castleman disease, who were HHV8 positive, improved upon neutralization of human IL-6 activity [95].”
• Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. (2014, background): “Two open-label clinical trials of tocilizumab for Castleman disease showed good patient responses (Nishimoto et al., 2000, 2005).”